lOMoARcPSD|26582732
Lomoarcpsd|26582732
NURS 635 Final Study Guide
2025
Advanced Pharmacology (Grand Canyon University)
1. Pharmacokinetics
The process by
which drugs are ab
sorbed, distributed
within the body, me
tabolized, and ex
Creted.
2. The route of administration with highest bioavail Intravenous
Ability
3. Steady state (SS) is reached in what time frame 4-5 half lives of a
drug
4. Zero order (non-linear) pharmacokinetics Drug is metabolized
at a constant rate
per unit time
Downloaded by NELSON KIIRU ()
, lOMoARcPSD|26582732
5. Steps of drug development Phase 1 preclinical
research with animal
testing
Phase 2 human sub
jects for med safety
Phase 3 humans
comparing drug to
accepted meds or
placebo
FDA review of re
sults post-
marketing study
6. Angiotensin-converting enzyme (ACE) inhibitors lower blood pres
MOA sure by inhibiting the
Conversion of an
giotensin I (an inac
tive enzyme) to an
giotensin II (a potent
vasoconstrictor)
7. Aceis ending -pril
8. Important side effects of aceis (2) Cough, angioedema
9. Arbs end in? -sartan
Downloaded by NELSON KIIRU ()
, lOMoARcPSD|26582732
10. Arbs MOA Block angiotensin-2
type 1 receptors
(AT1 receptor)
Decrease BP via ar
teriolar and venous
dilation
Block aldosterone
secretion (de
creased Na2+ and
H2O retention)
Does NOT increase
Bradykinin levels
Decrease diabetic
nephrotoxicity
11. % of htn that are essential (primary) 90%
12. Nitrates are contraindicated for pts w/ PDE-5 inhibitors
(sildenafil and varde
nafil)
13. Alpha-1 adrenergic stimulation results in Vasoconstriction and
increased blood
pressure
14. Alpha 1 adrenergic blockade results in vasodilation and re
Duced blood pres
sure
15. Beta 1 adrenergic stimulation by beta agonists re- increased heart rate
sults in increased blood
Pressure, increased
cardiac output
16. Beta blockers ending -olo
Downloaded by NELSON KIIRU ()
Lomoarcpsd|26582732
NURS 635 Final Study Guide
2025
Advanced Pharmacology (Grand Canyon University)
1. Pharmacokinetics
The process by
which drugs are ab
sorbed, distributed
within the body, me
tabolized, and ex
Creted.
2. The route of administration with highest bioavail Intravenous
Ability
3. Steady state (SS) is reached in what time frame 4-5 half lives of a
drug
4. Zero order (non-linear) pharmacokinetics Drug is metabolized
at a constant rate
per unit time
Downloaded by NELSON KIIRU ()
, lOMoARcPSD|26582732
5. Steps of drug development Phase 1 preclinical
research with animal
testing
Phase 2 human sub
jects for med safety
Phase 3 humans
comparing drug to
accepted meds or
placebo
FDA review of re
sults post-
marketing study
6. Angiotensin-converting enzyme (ACE) inhibitors lower blood pres
MOA sure by inhibiting the
Conversion of an
giotensin I (an inac
tive enzyme) to an
giotensin II (a potent
vasoconstrictor)
7. Aceis ending -pril
8. Important side effects of aceis (2) Cough, angioedema
9. Arbs end in? -sartan
Downloaded by NELSON KIIRU ()
, lOMoARcPSD|26582732
10. Arbs MOA Block angiotensin-2
type 1 receptors
(AT1 receptor)
Decrease BP via ar
teriolar and venous
dilation
Block aldosterone
secretion (de
creased Na2+ and
H2O retention)
Does NOT increase
Bradykinin levels
Decrease diabetic
nephrotoxicity
11. % of htn that are essential (primary) 90%
12. Nitrates are contraindicated for pts w/ PDE-5 inhibitors
(sildenafil and varde
nafil)
13. Alpha-1 adrenergic stimulation results in Vasoconstriction and
increased blood
pressure
14. Alpha 1 adrenergic blockade results in vasodilation and re
Duced blood pres
sure
15. Beta 1 adrenergic stimulation by beta agonists re- increased heart rate
sults in increased blood
Pressure, increased
cardiac output
16. Beta blockers ending -olo
Downloaded by NELSON KIIRU ()
